iJRASET
International Journal For Research in Applied Science and Engineering Technology

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** IV **Month of publication:** April 2025

DOI: https://doi.org/10.22214/ijraset.2025.69220

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

Review on Herpes Zoster

Ms. Shruti Balasaheb Choure[1], Ms. Rushali Bedjawalge[2], Mr. Nitin Gawai[3], Ms. Vaishnavi Gavhane[4], Mr. Vivek Patil[5]
B. Pharmacy Department, Mahadev Kanchan College of pharmaceutical education and research, Uruli Kanchan, Pune, Maharashtra, India

Abstract: ***The Varicella-Zoster Virus (VZV), which is latent in the dorsal root ganglia following a first infection (chickenpox), can reactivate to cause Herpes Zoster, sometimes referred to as shingles. It usually appears as a severe, vesicular rash that is limited to a single dermatome and mostly affects elderly adults and immunocompromised people. In addition to causing severe neuropathic pain, the condition can cause secondary bacterial infections, ocular involvement, and post herpetic neuralgia (PHN). To lessen the intensity and duration of symptoms, prompt identification and antiviral medication beginning are crucial. The frequency and consequences of illness in older people have been considerably decreased by immunization advancements, especially the recombinant zoster vaccine (Shingrix). Despite these developments, there are still difficulties in treating chronic pain and creating treatments that target dormant viral reservoirs. In addition to outlining current issues and potential research avenues for better patient care, this review covers the aetiology, pathophysiology, clinical characteristics, diagnosis, treatment options, and recent advancements in the prevention and management of herpes zoster.***

Keywords: Herpes Zoster, Shingles, Varicella-Zoster Virus (VZV), Post herpetic Neuralgia, Antiviral Therapy, Shingrix Vaccine, Neuropathic Pain, Dermatome, Viral Reactivation, Elderly Patients, Immunocompromised, Viral Latency, Vaccination, Acyclovir, Neurological Complications.

I. INTRODUCTION

A painful, blistering rash that usually forms in a band-like pattern on one side of the body or face is the hallmark of Herpes Zoster, sometimes referred to as shingles. The varicella-zoster virus (VZV), which also causes chickenpox, reactivates to produce the illness [1]. The virus stays latent in the sensory nerve ganglia after a person has healed from chickenpox, and it may reactivate later in life to cause herpes zoster. Since elderly adults and immunocompromised people are more likely to experience this reactivation, it poses a serious public health risk, especially as the global population ages. The name "zoster," which refers to the traditional belt-like distribution of the rash along dermatomes, is derived from the Greek word for "girdle." Herpes zoster usually does not cross the midline and only affects one dermatome. Nonetheless, the illness may spread among immunocompromised people, impacting several dermatomes or even visceral organs [2]-[3].



FIG.1: HERPES ZOSTER [1]

II. ETIOLOGY

The Varicella-Zoster Virus (VZV), a member of the Herpesviridae family, reactivates to cause Herpes Zoster. Usually occurring in infancy, the original VZV infection presents as varicella, or chickenpox. Following recovery, the virus stays dormant in the spinal or cranial nerves' sensory dorsal root ganglia. Herpes zoster is caused by the reactivation of this latent virus, which frequently occurs year's later [4]-[5].

Although the precise causes of reactivation remain unclear, a number of risk factors have been found. As the immune system deteriorates with age (immunosenescence), growing older is the biggest risk factor. Immunosuppression brought on by diseases like HIV/AIDS, cancer, or the use of immunosuppressive drugs (such corticosteroids or chemotherapy) are other contributory factors [6]-[7].

People may also be more susceptible to reactivation if they have experienced trauma, physical or mental stress, or certain chronic conditions like diabetes or renal failure. Although it happens less commonly, herpes zoster can occasionally strike immunocompetent people as well. Crucially, people who have never had chickenpox or who have not had the vaccination can get varicella from a person who has shingles by coming into close touch with the vesicular fluid; however, they will get chickenpox instead of shingles [8]-[9].

III. PATHOPHYSIOLOGY

The latent period that follows the first varicella infection is when the pathophysiology of herpes zoster starts. The Varicella-Zoster Virus goes latent in the sensory nerve ganglia, namely the dorsal root ganglia, cranial nerve ganglia (particularly the trigeminal nerve), or autonomic ganglia after chickenpox has resolved [10].

Particularly for VZV, cell-mediated immunity declines with ageing or immunological impairment. The virus can reactivate and start replicating in the neuronal cell bodies as a result of this compromised immune surveillance. When VZV is reactivated, it goes to the skin via sensory nerves, where it causes inflammation of the nerve and surrounding tissues, which results in the typical dermatomal rash [11].

A neuro inflammatory response comprising T cell infiltration, macrophage infiltration, and cytokine release results from the reactivation. Acute neuritis (pain in the nerves) and the possibility of post herpetic neuralgia (PHN) are caused by this inflammation, which damages the neurons and surrounding tissues [12].

PHN is a chronic pain disorder brought on by VZV-induced irreversible damage or malfunction of peripheral and central nervous system components. Furthermore, the virus can travel beyond the skin and nerves in immunocompromised people, perhaps damaging the brain, liver, or lungs and resulting in encephalitis or visceral dissemination [13].



FIG.2: HERPES ZOSTER

IV. SYMPTOMS

The prodromal phase of herpes zoster lasts two to three days and is marked by localized pain, burning, itching, or tingling in a particular dermatome. Depending on the region, some people may also have fever, malaise, headache, and photophobia during this period, which might be signs of appendicitis or myocardial infarction [14].

Following the prodrome, a unilateral erythematous rash appears at the start of the acute phase, which quickly develops into vesicles containing clear fluid. After 7–10 days, these vesicles finally become pustular and crust over, going away in 2–4 weeks. The rash usually affects the thoracic, cranial, or lumbar nerves and has a dermatomal distribution. Seldom does it cross the midline of the body [15].

The most noticeable and upsetting sign is pain. It might be searing, throbbing, stabbing, or sharp, and in certain situations, it lasts even after the rash goes away. Post herpetic neuralgia (PHN) is the name given to this chronic pain, which is more prevalent in older people [16].

Complications arise when certain nerves are affected. For instance, the trigeminal nerve in herpes zoster ophthalmic us can harm the eye, while the facial and auditory nerves in Ramsay Hunt syndrome can induce facial paralysis and hearing loss. Severe instances may be accompanied by widespread symptoms such as fever and exhaustion [17].

V. DIAGNOSIS

The main clinical criteria for diagnosing herpes zoster are the patient's symptoms and the emergence of the distinctive rash. Unilateral vesicular eruptions limited to a single dermatome are among the defining symptoms, which may be preceded or followed by burning, tingling, or severe pain in the afflicted region. The rash usually follows a dermatomal distribution and does not reach the midline of the body [18].

In most situations, laboratory testing is not required. However, further testing could be necessary in cases of disseminated zoster, immunocompromised individuals, or unusual presentations. Polymerase Chain Reaction (PCR), which finds VZV DNA in blood, cerebrospinal fluid, or skin lesions, is the most sensitive diagnostic method. When there are no outward signs of VZV, such in zoster sine herpete (pain without rash), PCR is very helpful [19].

Additional diagnostic techniques include Tzanck smear, which finds multinucleated giant cells in skin scrapings, and Direct Fluorescent Antibody (DFA) testing, which finds VZV antigens in vesicular fluid. PCR is more sensitive and specific than these tests, nevertheless. Although it takes time and is not as commonly employed, viral culture may also be carried out. [20].

Since most people have VZV antibodies from previous chickenpox infections or vaccinations, serologic testing is not useful in identifying current illness [21]

VI. RISK FACTORS

Herpes zoster is caused by the Varicella-Zoster Virus (VZV) reactivating due to a number of risk factors. The most important determinant is age; those over 50 are most at risk since their cell-mediated immunity is deteriorating. The latent virus can become active because aged people frequently show a decreased immune surveillance [22].

Reactivation is considerably more likely in immunocompromised conditions including HIV/AIDS, organ transplantation, cancer treatment, and long-term use of corticosteroids or immunosuppressive medications. Individuals who suffer from autoimmune conditions, such as rheumatoid arthritis or lupus, are also more vulnerable [23].

Another significant factor is stress, both mental and physical, which may have a suppressive influence on immunological function. Chronic conditions that increase vulnerability include diabetes mellitus, renal illness, and chronic obstructive pulmonary disease (COPD) [24].

Although some research indicates a slightly greater occurrence in females, gender may not have a significant impact. Furthermore, compared to a natural infection, those who had chickenpox as children or who had the live attenuated varicella vaccination can have a distinct risk profile [25].

Last but not least, family history and genetic susceptibility may possibly affect the risk of getting shingles, however further study is required to validate these links [26].

VII. TREATMENT

For herpes zoster to be effectively managed, therapy must begin as soon as possible. Reducing viral replication, reducing the length of symptoms, reducing pain, and avoiding consequences like post herpetic neuralgia (PHN) are the main goals.

Ideally, antiviral treatment should begin within 72 hours of the rash appearing. Antivirals that are often recommended include:

800 mg of acyclovir five times a day

1000 mg of valacyclovir three times a day

500 mg of Famciclovir three times a day

These substances lessen viral shedding, neuralgia, and rash development by blocking viral DNA replication. Intravenous acyclovir is administered to hospitalized or immunocompromised individuals.

One important component of therapy is pain control. Acetaminophen or NSAIDs can be used to treat mild to severe discomfort. Drugs including duloxetine, amitriptyline, pregabalin, and gabapentin work well for neuropathic pain. It is also possible to apply capsaicin cream or topical lidocaine patches.

Certain individuals may be administered corticosteroids to help with inflammation and acute pain, but they must be used carefully because they do not lower the risk of PHN.

Referrals to specialists should be made right away for patients with involvement of the cranial nerve or eyes. Important supporting measures during recuperation include getting enough sleep, being hydrated, and taking care of your skin [27]-[28].

VIII. FUTURE SCOPE OF STUDY

Future Herpes Zoster research will focus on a number of crucial areas. The creation of more potent vaccinations is one potential direction, especially for high-risk groups like the immunocompromised. Future studies might concentrate on improving Shingrix's long-term immunity, administration systems, and worldwide accessibility, notwithstanding the recombinant zoster vaccine's demonstrated excellent effectiveness [29].

Additionally, there is a rising need to investigate new antiviral drugs with better pharmacokinetics and fewer adverse effects, particularly for individuals who are toxic or resistant to existing medications. Research on combination treatments, such as immune modulators and antivirals, may improve the treatment of severe or complex zoster patients.

Further research is also necessary to comprehend the molecular processes behind viral latency and reactivation, since this might aid in the development of focused therapies. Therapeutic approaches to eradicate latent VZV from brain tissues may someday result from developments in gene editing and CRISPR technologies.

The treatment of post herpetic neuralgia, a difficult consequence, is another crucial field. Patient outcomes can be greatly enhanced by researching biological indicators for PHN prediction and creating novel analgesic medications or neuroprotective medicines.

Additionally, especially in low-resource contexts, public health initiatives must concentrate on cost-effective immunization techniques, screening, and awareness [30].

IX. CONCLUSION

Vaccination, especially with the Shingrix vaccine, has emerged as a highly effective preventive tool, drastically reducing the incidence and severity of herpes zoster and its complications. Future research holds promise in refining treatment protocols, understanding the virus's latency mechanisms, and developing more robust preventive strategies.

In conclusion, a multifaceted approach involving early detection, patient education, effective vaccination, and continued research is essential for reducing the global impact of herpes zoster.

The frequency and severity of herpes zoster and its sequelae have been significantly reduced by vaccination, particularly with the Shingrix vaccine. Future studies might help improve treatment regimens, comprehend the mechanics underlying the virus's latency, and create stronger preventative measures.

In conclusion, minimizing the worldwide impact of herpes zoster requires a multimodal strategy that includes early identification, patient education, efficient immunization, and ongoing research.

REFERENCES

[1] Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369(3):255-263.
[2] Dworkin RH, et al. Recommendations for the management of Herpes Zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26.
[3] Gilden DH, et al. Neurologic complications of the reactivation of Varicella-Zoster virus. N Engl J Med. 2000;342(9):635–645.
[4] Johnson RW, Rice AS. Postherpetic neuralgia. N Engl J Med. 2014;371(16):1526–1533.
[5] Whitley RJ. A 70-year-old woman with shingles: review of herpes zoster. JAMA. 2009;302(1):73-80.
[6] Yawn BP, et al. Incidence and complications of Herpes Zoster in the general population. Mayo Clin Proc. 2007;82(11):1341–1349.
[7] Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58(1):9–20.
[8] Schmader KE. Herpes zoster in older adults. Clin Infect Dis. 2001;32(10):1481–1486.
[9] Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2 Suppl):S3–12.
[10] Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002;347(5):340–346.
[11] CDC. Shingles (Herpes Zoster) Clinical Overview. https://www.cdc.gov/shingles
[12] Oxman MN, et al. A vaccine to prevent Herpes Zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284.
[13] Lal H, et al. Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
[14] Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274–280.
[15] Tseng HF, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–196.
[16] Kawai K, et al. Global varicella and herpes zoster burden: a systematic review. BMC Infect Dis. 2014;14:1–10.
[17] Gershon AA, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.
[18] Arvin AM. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352(22):2266–2267.
[19] Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol. 2007;57(6 Suppl):S136–142.

[20] Harpaz R, et al. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1–30.
[21] Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489–497.
[22] Schmader KE, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–928.
[23] Dooling KL, et al. Recommendations of the ACIP for use of Herpes Zoster vaccines. MMWR. 2018;67(3):103–108.
[24] Johnson RW, et al. The impact of herpes zoster and postherpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.
[25] Sato K, et al. Diagnosis and management of herpes zoster: J Dermatol. 2021;48(5):647–657.
[26] Dworkin RH, et al. Interventional management of neuropathic pain: Clinical practice guidelines. Pain. 2013;154(11):2249–2261.
[27] Oxman MN, Levin MJ. Vaccination against Herpes Zoster and postherpetic neuralgia. J Infect Dis. 2008;197(Suppl 2):S228–236.
[28] Wareham DW, Breuer J. Herpes zoster. BMJ. 2007;334(7605):1211–1215.
[29] Bader MS. Herpes zoster: Diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013;125(5):78–91.
[30] Sampathkumar P. Herpes zoster: an overview. Cleveland Clin J Med. 2002;69(9):725–730.



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY